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(DEPVIT): trial design and protocol
Tom H Margrain1*, Claire Nollett1, Julia Shearn1, Miles Stanford3, Rhiannon Tudor Edwards4, Barbara Ryan1,
Catey Bunce5, Robin Casten6, Mark T Hegel7 and Daniel J Smith2Abstract
Background: The prevalence of depression in people with a visual disability is high but screening for depression
and referral for treatment is not yet an integral part of visual rehabilitation service provision. One reason for this
may be that there is no good evidence about the effectiveness of treatments in this patient group. This study is the
first to evaluate the effect of depression treatments on people with a visual impairment and co morbid depression.
Methods /design: The study is an exploratory, multicentre, individually randomised waiting list controlled trial.
Participants will be randomised to receive Problem Solving Therapy (PST), a ‘referral to the GP’ requesting treatment
according to the NICE’s ‘stepped care’ recommendations or the waiting list arm of the trial. The primary outcome
measure is change (from randomisation) in depressive symptoms as measured by the Beck’s Depression Inventory
(BDI-II) at 6 months. Secondary outcomes include change in depressive symptoms at 3 months, change in visual
function as measured with the near vision subscale of the VFQ-48 and 7 item NEI-VFQ at 3 and 6 months, change
in generic health related quality of life (EQ5D), the costs associated with PST, estimates of incremental cost
effectiveness, and recruitment rate estimation.
Discussion: Depression is prevalent in people with disabling visual impairment. This exploratory study will establish
depression screening and referral for treatment in visual rehabilitation clinics in the UK. It will be the first to explore
the efficacy of PST and the effectiveness of NICE’s ‘stepped care’ approach to the treatment of depression in people
with a visual impairment.
Trial registration: ISRCTN46824140Background
The presence of a visual impairment is known to increase
the risk of depression and it is an independent predictor
of suicide in the elderly [1,2]. Epidemiological studies
indicate that the prevalence of depression in visually
impaired older adults living in the UK is 13.5% compared
to just 7.4% for those without a visual impairment [3].
At the time visually impaired people most need help,
when they are accessing vision rehabilitation services,
data from North America indicates that the prevalence of
depression is higher still at about 30% [4-7].
Low vision rehabilitation services operate at the inter-
face between health and social care and, in the UK, typ-
ically involve optometrists working with social services* Correspondence: margrainth@cardiff.ac.uk
1School of Optometry and Vision Sciences, Cardiff University, Cardiff CF24
4LU, UK
Full list of author information is available at the end of the article
© 2012 Margrain et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand the voluntary sector. The aim of this intervention is
to promote independent [8] living by reducing the dis-
ability associated with visual impairment. More specific-
ally, people with low vision are provided with practical
solutions to specific problems e.g. by providing magni-
fiers to help with reading, improved lighting and modifi-
cations to the home [9]. However, although these
services have been shown to reduce disability and people
appreciate the low vision aids provided, their reported
effects on overall quality-of-life have been modest [10-12].
One contributory factor is likely to be untreated depres-
sion in this patient group. Depression is not only disab-
ling in its own right but is very likely to act as a barrier
to good vision rehabilitation outcomes [13,14].
Despite the fact that people with a visual impairment
have an increased risk of depression, depression screen-
ing and referral for treatment is not currently part of
vision rehabilitation service provision. One reason foral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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evidence about the effectiveness of depression treatments
in this specific patient group. For example, although the
National Institute for Health and Clinical Excellence
(NICE) have issued guidance on the management and
treatment of depression in people with chronic health
problems there is no evidence about the effectiveness of
the recommended ‘stepped care’ approach in people with
a visual impairment [15]. The ‘stepped care’ treatment
options include: physical activity programmes, group-
based peer support (self-help) programmes, individual
guided self-help programmes based on the principles
of CBT including behavioural activation and Problem
Solving Therapy (PST) and, antidepressants. Although
there is no direct evidence about the effectiveness of
these interventions in people with depression and a
visual impairment, the ability of PST to prevent the onset
of depression in people with age-related macular degen-
eration, the leading cause of visual impairment in the
developed world, has been studied [8]. In that study PST
was shown to be successful at 2 months but the effects
were less impressive at 6 months.
The Depression in Visual Impairment Trial (DEPVIT)
will establish depression screening in several UK based
vision rehabilitation centres and obtain preliminary data
about the treatment effects associated with the stepped
care approach recommended by NICE and PST. More
specifically, DEPVIT aims to estimate the prevalence of
depressive symptoms using the Geriatric Depression
Scale (GDS-15) in an observational study of consecutive
attendees of low vision services in England and Wales,
and compare 2 interventions, PST and ‘referral to the
GP’, against a waiting list control for newly-diagnosed
low vision patients with depressive symptoms in an
exploratory randomised controlled trial. Subsidiary aims
include determining what action GPs take in response to
a referral for depressive symptoms in this patient group,
determining the acceptability of these interventions to
patients and establishing economic information about
the cost to roll-out a psychological problem solving
based intervention for people experiencing sight loss
and how well standard economic tools work with people
experiencing sight loss.
Methods/design
This is an exploratory, multicentre, individually ran-
domised controlled trial. Figure 1 summarises the study
design and the flow of patients through the trial.
The interventions
This trial involves 2 active interventions PST and ‘referral
to the GP’ and a ‘waiting list control’.
The PST intervention evaluated in this study is a
behavioural therapy that has been specifically designed forpeople with a visual impairment [8]. This intervention
involves a trained psychological therapist working with the
patient in their own home or at one of the research centres.
Over a 6–8 week period, patients are taught a 7-step
method for approaching and solving their problems. The
steps are: (1) defining the problem; (2) establishing realistic
goals; (3) brainstorming solutions; (4) implementing deci-
sion making guidelines (Pros versus Cons); (5) choosing a
preferred solution; (6) implementing the solution; and (7)
evaluating the outcome. The PST intervention will also in-
clude additional self-help materials for patients e.g. materials
concerning an explanation of depression, a discussion on
the importance of treating depression, and a description of
the various treatment options as well as vision related sign
posting materials. This type of behavioural therapy is an
individualised guided self help approach consistent with
NICE guidelines [15]. Optometrists providing the low vision
assessment will share the patient’s ‘treatment plan’ with the
therapist (via a brief report) so that the therapist can help
the patient implement the optometrist’s recommendations
via the PST framework if this is what the patient wishes. To
ensure the fidelity of this intervention the PST therapists
will be trained by Dr Mark Hegel the Clinical Psychologist
who originally designed the PST intervention used in 2007
by Rovner, Casten et al, [8]. With the participants consent,
each PST intervention will be taped and one third of ran-
domly selected tape recordings will be reviewed to
ensure the fidelity of the intervention.
The second intervention is ‘referral to the GP’. A care-
fully crafted referral letter will inform the GP that their
visually impaired patient has screened positive for a pos-
sible depressive disorder and invites them to offer the
patient an assessment and treatment as per NICE guide-
lines for the management of depression. This is a prag-
matic intervention and we acknowledge that GPs may or
may not adhere to NICE guidelines i.e. we propose to
evaluate the effectiveness of the referral, not ‘best prac-
tice’ as described by NICE. The fidelity of this inter-
vention will be assessed by recording the number of
correctly addressed referral letters sent.
The final arm of the study is a ‘waiting list control’.
Patients in this arm of the trial will be referred to their
GP using the referral letter described above after the
6 month outcome measure. A ‘waiting list control’ pro-
vides people taking part in the study with a better level
of care than ‘treatment as usual’ because depressive
symptoms are currently ignored and there is no referral.
The fidelity of this intervention will be assessed by ask-
ing people at 6 months about any treatments received
during the time of the study.
In addition to the interventions listed above, all partici-
pants in the study will have a follow up vision rehabilitation
appointment 6 weeks after the initial appointment.
Follow up appointments of this type are typical for
“CONTROL”  
After 6 weeks: follow up 
LVA (n=34) 
“PST” 
Within 2 weeks: 
Problem-solving 
treatment begins 
“LETTER”
Within 2 weeks: Letter 
to the GP informing him 
/ her of GDS score 
After 6 weeks: follow up 
LVA (n=34) 
After 6 weeks: follow up 
LVA (n=34) 
After 3 months: (n=31) 
Telephone interview: 
VFQs, BDI-II, ICECAP &
EQ-5D
After 3 months: (n=31) 
Telephone interview: 
VFQs, BDI-II, ICECAP & 
EQ-5D
After 3 months: (n=31) 
Telephone interview: 
VFQs, BDI-II, ICECAP & 
EQ-5D
Consecutive attendees at low vision services in SE Wales and London (n=1000) 
All complete routine pre assessment questionnaire which includes: 7 item NEI VFQ & 
GDS-15. An additional brief information sheet about the study will be included.  
GDS score of 6 or more 
(n=300)
GDS score of less than 6 
(n=700) routine low vision 
assessment  
Low Vision Assessment (LVA) 
All are given detailed information about the study (orally and in writing) and copies of the 
questionnaires (7 item NEI VFQ, near subscale VFQ-48, BDI-II, EQ-5D, ICECAP & CSRI) 
that will form the basis of the baseline telephone interview.  
INFORMED CONSENT OBTAINED (n=100) 
Baseline biographical information extracted from participant’s notes 
BASELINE TELEPHONE INTERVIEW 
(within 1 week)  
7 item NEI VFQ +VFQ-48 near 
subscale, BDI-II & EQ-5D, CSRI, 
ICECAP, Cognitive Screen (referral for 
medication evaluation for those with a 
score of 29 or more on the BDI-II) then,
After 6 months: (n=24) 
Telephone interview: 
VFQs, BDI-II, EQ-5D, 
ICECAP, CSRI 
& GDS-15 
Letter to GP informing 
him / her of GDS score
After 6 months: (n=24) 
Telephone interview: 
VFQs, BDI-II, EQ-5D, 
ICECAP, CSRI 
& GDS-15 
Questions about 
outcome of referral and 
acceptability of this 
intervention
After 6 months: (n=24) 
Telephone interview: 
VFQs, BDI-II, EQ-5D, 
ICECAP, CSRI 
& GDS-15 
Questions about 
acceptability of PST 
intervention 
After 9 months 
Questions about 
outcome of referral and 
acceptability of this 
intervention & GDS-15  
Participants still screening positive for depression (GDS-15) will be offered a GP referral. 
All participants thanked for their involvement in study and feedback on study provided. 
Those scoring 2 
or 3 on the 
suicidal ideation 
scale (BDI-II) will 
be referred to GP 
and will not take 
part in the trial. 
Figure 1 DEPVIT Trial Design.
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http://www.biomedcentral.com/1471-244X/12/57people who appear depressed or are obviously struggling
at the initial low vision assessment.
Outcome measures
The primary outcome will be the change in depressive
symptoms, from randomisation to 6 months, as mea-
sured by the Becks Depression Inventory (BDI-II). The
BDI-II is a reliable, valid and widely used outcome
measure for depression [16,17].
Secondary outcome measures in this exploratory trial
will include change (from randomisation to 3 and
6 months) in visual disability as measured using the 7item NEI VFQ and the near vision subscale of the VFQ-
48 and, change in ‘generic health related quality of life’
as measured using the EQ-5D [18,19]. Additional
secondary outcomes measured at 6 months will include
the proportion of people still screening positive for de-
pression as measured with the GDS-15, participant’s use
of services as determined using a Client Services Receipt
Inventory (CSRI) and an economic measure of ‘capabil-
ity and wellbeing’ the ICECAP-O [20-22]. At the end of
this exploratory trial participants will be asked about any
treatments for depression they have received during the
trial period (specifically, whether they received regular
Margrain et al. BMC Psychiatry 2012, 12:57 Page 4 of 8
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mental health team, supportive psychotherapy, counsel-
ling, problem-solving therapy, cognitive-behavioural ther-
apy or antidepressant therapy). They will also be asked
about the acceptability of any interventions received.
Participants in the waiting list control group who still
screen positive for depression (GDS-15, 6+) will be referred
to their GP. And, 3 months later asked about any treat-
ment for depression received as a result of the referral.
All trial outcomes will be assessed by telephone inter-
view by the Study Coordinator who will be masked to
the treatment intervention. In order to minimise ‘loss to
follow up’, interviews will be based on a standard script
and will remind participants of their valuable contribu-
tion and the need to complete the study.
Sample size
During the course of the study 1000 consecutive atten-
dees will be screened. At the outset we anticipate that
about 1/3 will screen positive for depression and be eli-
gible, and that of those, about 100 will consent to take
part. This target of 100 patients recruited into the trial is
realistic and achievable. Resource limitations require us
to cap the number of participants to 150.
Since this study is exploratory we will predominantly
use descriptive methods to report results. That is, this
study is not powered to look at differences in outcomes
(there is no data upon which to determine the sample
size). However, to give the reader some indication about
the power of this exploratory trial, if we assume that
those entering the trial are moderately depressed (aver-
age BDI-II score of 30, SD 10.5) and, if the trial finishes
with only 20 participants per treatment group, we would
have 83% power to detect a difference in post treatment
means of 10 (a change of 10 units corresponding to a
moderately important clinical difference) with a 5% two-
sided significance level.
Recruitment
Participants will be identified and recruited from 7 com-
munity based low vision rehabilitation centres in South
Wales and from one large secondary care based low vi-
sion rehabilitation centre at Guys and St Thomas’ NHS
Trust, London [23]. Based on known activity in these
recruitment centres we anticipate that the 7 sites in
Wales will screen approximately 500 people in total and
that a similar number will be screened in London.
Inclusion criteria
Adults (18+ years of age) with a score of at least 6 on
the GDS-15 (administered as part of the routine pre as-
sessment questionnaire) will be the inclusion criterion
for this study.Exclusion criteria
To ensure our results are applicable to the population
we propose to keep the exclusion criteria to a minimum,
specifically: 1) those who have already had a low vision
assessment within the previous 12 months, 2) those who
are referred to the clinic in error (i.e. so visually
impaired that low vision care and follow up are inappro-
priate or, so visually able (e.g. following refraction) that
there are no low vision needs), 3) those already being
treated for depression including psychotherapeutic and
psychopharmacological treatments, 4) inability to under-
stand English, 5) Inability to use the telephone e.g.
caused by very poor hearing, 6) severe medical illness
that would preclude participation in a 6 month study, 7)
a score of 2 or 3 on the BDI-II question about suicidal
ideation, all people in this group will be urgently referred
to their GP, 8) those screening positive for significant
cognitive / memory problems as determined with a
modified version of the MMSE will be excluded.
Trial procedures: consent, baseline assessments
and randomisation
The low vision rehabilitation services in Wales and
London now include a routine self-complete pre assess-
ment questionnaire (made up of the 7 item NEI VFQ
and GDS-15) which is given to patients one week before
their consultation. During the trial this will be accom-
panied by a Patient Information Sheet letting people
know that the low vision service they are about to attend
is taking part in a study. The sheet details the aims,
purpose and what is involved in participation in the
study. At the rehabilitation consultation, those satisfying
the inclusion criteria will be invited to take part by
the optometrist who provides the low vision rehabilita-
tion intervention.
The optometrists (who are trained to take informed
consent) will document the consultation using standard
clinical records and, for the purposes of this study,
a case report form. The GDS-15 will be reviewed at the
start of the hour long low vision assessment and all posi-
tive screening patients will be informed that they may be
eligible to take part in the study. Toward the end of the
low vision assessment a full verbal explanation of the
study will be provided to positive screening patients and
they will be asked if they would like to take part. Those
expressing an interest in taking part will then be
screened by the optometrist for exclusion criteria 1, 2, 3,
4, 5 & 6. Those still eligible will be given written copies
(large print) of the questionnaires that will be used in
the telephone interview to take home and will be asked
to provide their written informed consent.
Consenting patients will be contacted by the Study
Coordinator within 1 week to, make an appointment to
administer the cognitive screen and BDI-II to check for
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itional eligibility criteria will be enrolled in the study and
the other baseline outcome measures will be adminis-
tered. Those scoring 29 or more on the BDI-II at the
baseline interview have severe depressive symptoms and
in all cases a letter will be written to the person’s GP
requesting a ‘medication evaluation’.
Potential recruits who would like additional time to
consider enrolment, after the initial low vision assess-
ment will be contacted by phone by their low vision
practitioner one week later to find out “how they are
getting on”. If they then want to take part in the study
they will be booked back in to see the practitioner to
complete the study consent form. Participants who
screen positive for depression but who decline to take
part in the trial will be asked if they would like to be
referred to their GP anyway. The person’s decision will
be noted in the records e.g. if they decline referral. These
people will be asked if they are willing to provide their
consent for the use of anonymous baseline data.
Within one week of the baseline telephone interview,
participants will be randomised using computer generated
permuted blocks of varying sizes (unknown to investiga-
tors) stratified for study centre (Wales and London) and
for ‘medication evaluation’ only. To ensure that the Study
Coordinator is masked to treatment allocation, the Chief
Investigator will allocate participants to the different arms
of the trial.
For those assigned to the ‘referral to GP’ arm of the
trial, the letter to the GP will be posted on the day the
person was randomised and the participant will be asked
to make an appointment with their GP within 2 weeks.
For those assigned to PST, treatment will commence
within 2 weeks of randomisation. All participants will be
given a follow up vision rehabilitation appointment
6 weeks after the initial rehabilitation appointment.
The Study Coordinator will contact participants 3 and
6 months after randomisation to obtain outcome meas-
ure data.
Process evaluation
A process evaluation will be conducted to evaluate
whether the intervention was carried out in accordance
with the trial protocol. Specifically, all PST consultations
will be taped and 1/3 of them will be reviewed by the
research team to ensure the fidelity of this intervention.
The fidelity of the ‘referral to GP’ arm will be deter-
mined by noting the date the referral letter was sent to
the GP. After the 6 month outcome measure a letter will
be sent to each participant’s GP asking what treatments
/ action have taken place during the trial period. At the
end of the trial all participants will take part in an inter-
view to determine their level of satisfaction with the
service received and any action taken by the GP. Thisfinal interview will include qualitative questions about
what worked well and not so well.
Assessment of costs
We will also conduct an assessment of the direct costs
associated with the delivery of the PST intervention and
identify its key cost consequences e.g. reductions in
demands on other service. The cost of the intervention
will be assessed by monitoring the activity of the Psycho-
logical Therapist and the costs associated with travel to
and from participants’ homes.
The costs associated with the use of additional ser-
vices will be established using a telephone based Client
Service Receipt Inventory (CSRI) [21].
Analyses
Statistical analyses
We will tabulate the number of patients by GDS-15
Score. We will estimate the prevalence of depressive
symptoms (defined as a GDS-15 score of 6 or more)
with 95% confidence intervals computed by the exact
binomial method. We will use logistic regression to
assess whether factors such as age, sex, pathology and
site are associated with depressive symptoms. With a
sample size of 1000, a two sided 95% confidence interval
will extend 0.028 from the observed proportion for an
expected proportion of 0.3.
This trial is the first of its kind and hence ‘exploratory’.
For the trial, we will compare baseline characteristics of
the allocated groups to ensure the adequacy of random-
isation (including duration of visual loss). If outcome
data are not available for all randomised patients, we will
compare characteristics of those for whom it is available
with those for whom it is not to assess whether the
groups differ systematically. To retain the validity of the
randomisation process the analyses will be undertaken
on an intention-to-treat basis.
We will report average change in BDI scores in treat-
ment groups using the mean or median as appropriate
together with some indication of variability such as the
standard deviation or interquartile range. These results
will then be used to estimate the numbers of patients
required for a definitive study.
Missing data has the potential to bias our findings.
Hence we will attempt to minimise ‘loss to follow up’ by
making it clear to potential recruits what is required at
the outset, letting them know that completion of the
study is important and reminding them of the value of
their contribution when outcomes are assessed during
the scripted telephone interviews. We will document the
reasons for missing data and establish both the extent
and patterns of missing data in each arm of the trial.
We will also acknowledge the potential impact of miss-
ing data in our conclusions.
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level of depression, level of vision impairment, ethnicity,
functional ability and time since vision loss first identi-
fied) of those who did and did not consent to take part
in the trial to determine if we can predict who is likely
to benefit from depression screening.
We will also look for PST trainer effects (i.e. compare
outcomes of PST delivery in London and Wales). The
study design and scripted outcome measurements are
designed to minimise the possibility of masking violation
in this exploratory trial. We will however report any
masking violations descriptively.Analyses of costs
We will determine the direct costs of the psychological
problem solving based intervention for people experien-
cing sight loss. We will also determine preliminary data
on the incremental cost effectiveness of a home-based
problem solving psychological intervention, aimed to
support people experiencing sight loss, compared to
referral to primary care and a waiting list control.
From a public sector, multi-agency perspective we will:
fully cost the development, staff training and roll-out of
this problem-solving psychological intervention [24-26].
We will record study participant primary and secondary
care health service use, social care use and contacts with
voluntary sector agencies supporting blind and partially
sighted people (using an interviewer administered, tele-
phone-based Client Service Receipt Inventory (CSRI), as
one of the full battery of study measures, costed using
National unit costs and where necessary, local costs).
We will also conduct a primary cost effectiveness anal-
ysis (using the Geriatric Depression Scale (GDS-15) as
our measure of effectiveness); conduct a secondary cost-
utility analysis using EQ-5D (interviewer administered
by telephone) as our measure of utility to generate a cost
per QALY (ICER) and Cost Effectiveness Acceptability
Curve (CEAC) for comparison with the NICE ceiling of
£30,000 [25,27].
As this is a feasibility study we will pay particular
attention to the validity of EQ-5D in this group of
patients, comparing the 5 domains of EQ-5D (including
anxiety and depression) with, in particular, the depres-
sion measures used in this study [28].Discussion
This trial will be the first to evaluate the effectiveness
and acceptability of depression treatments in people with
a visual impairment. This study is significant because
about 155,000 visual rehabilitation appointments are
provided for people with a visual impairment in the UK
each year and about 1/3 of them are likely to have sig-
nificant depressive symptoms [29]. The trial willestablish depression screening and referral for treatment
in this high risk group.
This exploratory trial will produce data on the effects
of PST and ‘referral to the GP’ on depressive symptoms,
visual function, generic health related quality-of-life and
use of services. Together with the economic evaluation
and information about the acceptability of these inter-
ventions the data from this trial will inform the design
of a larger (phase III) randomised controlled trial.
Strengths of the study
To maximise the potential impact of PST, the research
team includes the original developers of this manualised
intervention. The PST intervention used in this study
draws on the significant experience of the research team
who have worked with people with a visual impairment
and depression for many years.
The ‘referral to GP’ arm of the trial is a pragmatic
intervention designed to find out what really happens in
response to a referral for depression. Although our refer-
ral letter encourages GPs to offer treatment according to
current NICE guidelines it is the effectiveness of the
referral we are evaluating not the ‘stepped care approach’
recommended by NICE. That is, we do not expect all
GPs to adhere to NICE guidelines. By contacting GPs
at the end of the trial and by speaking to participants
randomised to this arm of the study we should gain a
clear understanding of what actually happens following
a referral.
The study materials including the Patient Information
Sheet and Consent Form have been developed in collab-
oration with service users. The pre assessment question-
naire that includes the GDS-15 and the 7 item NEI VFQ
has been piloted extensively on people with a visual
impairment, including those with depression.
In line with MRC guidelines on good clinical practice
in clinical trials we have established an independent
Trial Steering Committee which will ensure that the
protocol is adhered to.
Challenges
Encouraging those with depression to engage with the
research project may be challenging given that their mo-
tivation is likely to be low. By getting their optometrist,
who has provided the vision rehabilitation intervention,
to describe the study and ask for consent we hope to
maximise recruitment.
The relationship between depression and visual impair-
ment is complex [13]. Hence, good outcomes are most
likely to be observed following good vision rehabilita-
tion and depression interventions i.e. both are required.
Whilst the research team have good control of the
depression interventions and will check their fidelity we
are not checking the rigor of the vision rehabilitation
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rehabilitation in Wales have been trained and accredited,
by Cardiff University, to provide a very specific type of
community based intervention delivered as part of the
“Welsh Low Vision Service” [23,30]. The optometrists at
the London site are experienced vision rehabilitation
practitioners but they have not been trained and accre-
dited in the same way. To minimise any differences in
the vision rehabilitation intervention the clinical leads of
the Welsh and London services have met to agree to a
standardised approach to low vision rehabilitation. This
standardised approach is documented in the master files
at all sites.
Conclusion
In summary, although recent evidence suggests that de-
pression is likely to be prevalent in people attending vi-
sion rehabilitation services, screening for depression and
referral for treatment is not currently part of service.
This study will for the first time establish depression
screening and referral for treatment in UK based vision
rehabilitation clinics. It will provide preliminary data on
the effects of ‘Problem Solving Therapy’ and a ‘referral
to the GP’ on depressive symptoms and visual function
in people with untreatable visual impairment. Informa-
tion about the effectiveness of depression treatments in
this group will help shape future service delivery.
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